NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Proposed Single Technology Appraisal (STA)

Pegaptanib sodium for the treatment of diabetic macular oedema

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Manufacturers/sponsors	General
 Manufacturers/sponsors Pfizer (pegaptanib sodium) Patient/carer groups Action for Blind People Afiya Trust Association of Blind Asians (ABA) Black and Ethnic Minority Diabetes Association (BEMDA) Black Health Agency Chinese National Healthy Living Centre Counsel and Care Diabetes UK Diabetes Research & Wellness Foundation 	 General Board of Community Health Councils in Wales British National Formulary Care Quality Commission Commissioning Support Appraisals Service Department of Health, Social Services and Public Safety for Northern Ireland Diabetes UK Cymru Medicines and Healthcare products Regulatory Agency National Association of Primary Care NHS Alliance NHS Commercial Medicines Unit NHS Confederation
Equalities National Council	NHS Quality Improvement Scotland
Eyecare Trust	Public Health Wales NHS Trust
Fight for Sight	Scottish Medicines Consortium
Insulin Dependent Diabetes Trust	
Insulin Pumpers UK	Possible comparator manufacturers
INPUT – Insulin Pump Therapy	Alimera Sciences (fluocinolone Alimera Sciences (fluocinolone)
Macular Disease Society	acetonide intravitreal implant)
Muslim Council of Britain	Coherent UK (photocoagulation) Coherent UK (photocoagulation)
Muslim Health Network Naturally of Oilds Organizations	KLS Martin Group (photocoagulation)Litechnica (photocoagulation)
Network of Sikh Organisations African	1
Organisation of Blind African Caribbeans	Lumenis UK (photocoagulation)Novartis Pharmaceuticals (ranibizumab)
 Royal National Institute of Blind 	 Quantel Medical (photocoagulation)
People (RNIB)	 Roche Products (bevacizumab)
Seeability	Topcon Great Britain (photocoagulation)
Sense	1 Spoot Croat Britain (priotocoagulation)
South Asian Health Foundation	Relevant research groups
Specialised Healthcare Alliance	Cochrane Eyes and Vision Group
Specific Eye Conditions (SPECS)	Diabetes Foundation
Surya Foundation	Heart Disease and Diabetes Research

National Institute for Health and Clinical Excellence

Provisional matrix for the proposed technology appraisal of pegaptanib sodium for the treatment of diabetic macular oedema

Issue date: November 2010 Page 1 of 3

Consultees	Commentators (no right to submit or appeal)
 Thomas Pocklington Trust Professional groups Association of British Clinical Diabetologists Association of Diabetes Specialist Nurses British Association for Services to the Elderly British Diabetic Association British Geriatrics Society College of Optometrists Diabetes Monitoring Forum National Diabetes Nurse Consultant Group National Pharmacy Association Primary Care Diabetes UK Royal College of General Practitioners Royal College of Physicians Royal College of Pathologists Royal College of Physicians Royal College of Physicians Royal Society of Medicine United Kingdom Clinical Pharmacy Association Others Department of Health NHS Harrow NHS Oldham Welsh Assembly Government 	Trust Institute of Ophthalmology, University College London MRC Clinical Trials Unit National Institute for Health Research Policy Research Institute on Ageing and Ethnicity Research Institute for the Care of Older People Evidence Review Group Evidence Review Group Institute for Health Research Health Technology Assessment Programme Associated Guideline Groups National Clinical Guidelines Centre Associated Public Health Groups tbc

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do share it. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

National Institute for Health and Clinical Excellence

Provisional matrix for the proposed technology appraisal of pegaptanib sodium for the treatment of diabetic

macular oedema

Issue date: November 2010 Page 2 of 3

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*.

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

National Institute for Health and Clinical Excellence

Provisional matrix for the proposed technology appraisal of pegaptanib sodium for the treatment of diabetic macular oedema

Issue date: November 2010 Page 3 of 3

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.